Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Atyr1923 symbols : LIFE save search
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis
Published: 2022-08-11 (Crawled : 12:20) - globenewswire.com
LIFE | $1.6 -1.23% -1.25% 160K
|
Health Technology
|
| O: 1.07%
H: 2.65%
C: -3.18%
atyr1923 treatment fda designation pharma fast track designation
aTyr Pharma Presents Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
Published: 2022-05-17 (Crawled : 13:20) - biospace.com/
LIFE | $1.6 -1.23% -1.25% 160K
|
Health Technology
|
| O: 2.27%
H: 3.81%
C: 1.59%
atyr1923 pharma conference international
aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis
Published: 2022-05-16 (Crawled : 19:00) - biospace.com/
LIFE | $1.6 -1.23% -1.25% 160K
|
Health Technology
|
| O: 0.0%
H: 5.23%
C: 0.65%
atyr1923 pharma phase 3
aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of Systemic SclerosisSecond U.S. orphan drug designation for efzofitimod clinical program
Published: 2022-04-13 (Crawled : 17:00) - biospace.com/
LIFE | $1.6 -1.23% -1.25% 160K
|
Health Technology
|
| O: 0.21%
H: 10.73%
C: 7.16%
atyr1923 treatment fda pharma drug program designation
aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
Published: 2022-04-01 (Crawled : 20:00) - biospace.com/
LIFE | $1.6 -1.23% -1.25% 160K
|
Health Technology
|
| O: 4.67%
H: 6.61%
C: -0.18%
atyr1923 pharma conference international
aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name
Published: 2022-01-13 (Crawled : 14:00) - biospace.com/
LIFE | $1.6 -1.23% -1.25% 160K
|
Health Technology
|
| O: -3.95%
H: 0.29%
C: -1.62%
atyr1923 announcement pharma
aTyr Pharma Announces FDA Orphan Drug Designation for ATYR1923 for Treatment of SarcoidosisCompany expects to initiate registrational trial of ATYR1923 in pulmonary sarcoidosis in 2022
Published: 2022-01-06 (Crawled : 15:30) - biospace.com/
LIFE | $1.6 -1.23% -1.25% 160K
|
Health Technology
|
| O: -1.1%
H: 2.78%
C: -0.56%
atyr1923 treatment fda drug trial orphan drug designation
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.